First-In-Class
Therapeutics to treat
Poorly Sensitive Cancers 

BiPER Therapeutics is a preclinical-stage biotech company founded in 2021 to develop and commercialize novel therapeutics. We are developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. BiPER 's name summarizes the original and unique approach of our first portfolio of therapeutics : Our drug candidates target BiP, an key protein involved in cancer cells survival and associated with poor prognosis of patients, triggering cancer cell death and tumour growth inhibition through ER (Endoplasmic Reticulum) Stress induction.

Resistance to standard chemotherapeutic treatments and poor responses to immune-based therapies represent major challenges in cancer treatment as many patients respond poorly or not at all to currently available treatment options.

​

BiPER Therapeutics aims to bridge this important treatment gap by developing novel therapeutic solutions based on these core principles: 

• Targeting the global metabolism of cancer cells
   

• Modulating the Endoplasmic Reticulum Stress (ER stress) a pathway involved in cancer treatment resistance
   

• Developing BPR series of First-In-Class small molecules selectively targeting BiP/GRP78 a key chaperone protein involved in ER stress
   

• Selectively activating cell death in cancer cells to treat resistant as well as sensitive cancers